Eicos Sciences

Eicos Sciences is a private, preclinical-stage biotech leveraging the established biology of prostacyclins to develop novel therapies for severe, underserved conditions. The company's platform centers on the anti-inflammatory, antiplatelet, and vasodilatory properties of PGI2 analogues, aiming to address high-need areas like frostbite and systemic sclerosis. While the company appears to be in an early operational phase with a basic website, its scientific premise targets clear unmet medical needs in niche vascular and inflammatory disorders.

Development of novel prostacyclin (PGI2) analogues leveraging their vasodilatory, antiplatelet, antiproliferative, and anti-inflammatory properties.

For systemic sclerosis, competition includes existing prostacyclin drugs (iloprost) and a growing pipeline of antifibrotics and immunomodulators. In frostbite and ECMO adjunct therapy, the competitive field is less crowded, but the pathways to approval and commercialization are less established.